drugset

drugset / Trial / NCT06684522

Upadacitinib as a Novel Treatment for Refractory Eyelid Dermatitis

NCT06684522 ↗

Phase 0 Recruiting 10 enrolled Northwestern University

NaSingle-groupOpen-labelTreatment

Summary

This study aims to assess the efficacy of upadacitinib in eyelid dermatitis that has not resolved with topical therapies and patch testing.

Timeline

Start: 2025-12-18
Primary completion: 2027-06
Completion: 2027-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Upadacitinib	Small molecule	15 mg	—

Indications